New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits With VENCLEXTA®/ VENCLYXTO® (Venetoclax) Combination in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)